News

Farydak® recommended for use across Europe

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive recommendation for the use of Farydak (panobinostat) as a treatment for relapsed and/or refractory myeloma patients who have received at least two prior treatments including Velcade® (bortezomib) and an immunomodulatory drug. Farydak is the first histone deacetylase (HDAC)…

Details

Abingdon Health announces commercial launch of Seralite® – FLC

Abingdon Health, a UK company specialising in rapid diagnostic technology, has announced the commercial launch of Seralite – FLC, a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The assay, designed as an aid to the diagnosis and management of myeloma. is a simple to use,…

Details

ASCO 2015 Annual Meeting highlights

Highlights of the key data presented at this year’s American Society of Clinical Oncology (ASCO) on 29 May – 2 June 2015 in Chicago, USA include: Results of the Phase III ELOQUENT-2 trial showing that addition of elotuzumab (anti-SLAM7 monoclonal antibody), to the combination of Revlimid and dexamethasone in relapsed and/or refractory myeloma patients increased…

Details

New Phase III trial of once-weekly versus twice-weekly carfilzomib

Amgen, the US biopharmaceutical company, has announced the start of a new global Phase III trial investigating the benefit of once-weekly carfilzomib (Kyprolis®) in combination with dexamethasone compared to the current US Food and Drug Administration (FDA) approved twice-weekly administration of carfilzomib for relapsed and or refractory myeloma patients who have previously been treated with…

Details

New trial of the novel drug Selinexor to commence in myeloma

Karyopharm Therapeutics Inc., the US-based clinical stage pharmaceutical company, has announced it is starting a new Phase IIb trial of its lead investigational drug, selinexor (KPT-330) in heavily pre-treated quadruply refractory myeloma patients who have not responded to prior Velcade, Revlimid®, Kyprolis® and Imnovid® treatment. Selinexor is a novel, oral selective inhibitor of nuclear export/SINE™…

Details

Study demonstrates feasibility of adoptive T-cell therapy in myeloma

A study, published recently in Science Translational Medicine, has shown for the first time that T cells taken from a patient’s own bone marrow is effective in treating myeloma. Researchers used adoptive T-cell transfer therapy in which either newly diagnosed or relapsed myeloma patients had their marrow-infiltrating lymphocytes harvested, activated and expanded, and then re-infused…

Details

First patient enrolled in Phase III ixazomib maintenance trial for myeloma

The Japanese pharmaceutical company, Takeda, has announced that the first patient has been enrolled into its Phase III trial of ixazomib as maintenance treatment for newly diagnosed myeloma patients who have responded to initial treatment but have not undergone high-dose therapy and stem cell transplantation. Ixazomib, an oral proteasome inhibitor, is currently being investigated as…

Details

MedImmune and Celgene to collaborate on anti-PD-L1 inhibitor programme for haematological malignancies

MedImmune, a subsidiary of AstraZeneca PLC, and Celgene are collaborating on a programme to develop and commercialise an anti-PD-L1 inhibitor, MEDI4736, for the treatment of myeloma and other haematological malignancies. MEDI4736 is a human anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody which works as an immune checkpoint inhibitor and enables the immune system to…

Details